UniProt/SwissProt ID: | PRDX1_HUMAN |
Description: | peroxiredoxin 1 [Source:HGNC Symbol;Acc:9352] |
Location: | chr1 p34.1 |
Node attribute: | substrate |
Phosphorylation site |
Position | PhosphoPeptide | Catalytic kinase | Source |
---|---|---|---|
S32 | KDISLsDYKGK | AhpC-TSA | PhosphoSitePlus |
T143 | ILRQItVNDLP | PhosphoSitePlus | |
Y194 | QKSKEyFSK | HPRD; phosphoELM | |
T90 | LAWVNtPKKQG | CDC2(CDK1 | RegPhos |
Y194 | QKSKEyFSKQK | 1-cysPrx_C | PhosphoSitePlus |
T90 | LAWVNtPKKQG | CDK1 | phosphoELM |
Y34 | ISLSDyKGKYV | AhpC-TSA | PhosphoSitePlus |
Y194 | QKSKEyFSKQK | RegPhos | |
T90 | LAWVNtPKKQG | AhpC-TSA | PhosphoSitePlus |
Y116 | TIAQDyGVLKA | AhpC-TSA | PhosphoSitePlus |
T183 | KPGSDtIKPDV | 1-cysPrx_C | PhosphoSitePlus; SysPTM |
T183 | KPGSDtIKPDV | HPRD; phosphoELM; RegPhos; SysPTM | |
T90 | LAWVNtPKKQG | CDC2 | RegPhos |
Dephosphorylation site |
PRDX1_HUMAN do not have dephosphorylation site. |
Mutation site |
Ensembl ID | Variation | Source | Cancer name | Pubmed |
---|---|---|---|---|
ENSP00000407034 | S126L | BIOMART | Breast Cancer | 21930507, 21930502 |
ENSP00000262746 | S126L | BIOMART | Breast Cancer | 21930507, 21930502 |
ENSP00000361150 | S24L | BIOMART | Breast Cancer | 21930507, 21930502 |
ENSP00000389047 | S126L | BIOMART | Breast Cancer | 21930507, 21930502 |
ENSP00000361152 | S126L | BIOMART | Breast Cancer | 21930507, 21930502 |
Differential expressed protein |
Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
---|---|---|---|---|---|---|
ENSP00000262746 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 17537172 | |
ENSP00000262746 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Down | 0.26 | 18646787 |
ENSP00000262746 | hepatitis B virus | Normal vs. Cancer | tissue | Down | 0.35 | 14726492 |
ENSP00000262746 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 17902640 | |
ENSP00000262746 | Breast Cancer | Treatment (Antiestrogen-sensitive vs. Antiestrogen-resistant) | cell line | Up | 2.4 | 14557597 |
ENSP00000262746 | Breast Cancer | Normal vs. Cancer | tissue | Up | 18257521 | |
ENSP00000262746 | hepatitis C virus | Normal vs. Cancer | tissue | Down | 0.5 | 16097030 |
ENSP00000262746 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Down | 17214954 | |
ENSP00000262746 | Hepatocellular Carcinoma | Metastasis | cell line | Down | 17214954 | |
ENSP00000262746 | Hepatocellular Carcinoma | Metastasis | cell line | Down | 17214954 | |
ENSP00000262746 | Hepatocellular Carcinoma | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | tissue | Up | 17593366 | |
ENSP00000262746 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | |
ENSP00000262746 | Lung Cancer | Treatment(none vs 20 mg/mL GTE treatment) | cell line | Up | 9.5 | 19137550 |
ENSP00000262746 | Lung Cancer | Treatment(none vs 40 mg/mL GTE treatment) | cell line | Up | 14 | 19137550 |
ENSP00000262746 | Gastric Cancer | Treatment (none vs. Vincristine-resistant) | cell line | Up | 16525997 | |
ENSP00000262746 | Gastric Cancer | Treatment (none vs. 5-fluorouracil treatment) | cell line | Up | 15 | 16900703 |
ENSP00000262746 | Breast Cancer | Normal vs. Cancer | tissue | Up | 3.3 | 20005186 |
ENSP00000262746 | Breast Cancer | Normal vs. Cancer | cell line | Up | 2.1 | 20052998 |
ENSP00000262746 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.3 | 20052998 |
ENSP00000262746 | Breast Cancer | Metastasis | cell line | Down | 0.62 | 20052998 |
ENSP00000262746 | chronic myeloid leukemia | Treatment (Imatinib-sensitive vs. Imatinib-resistant) | cell line | Down | 20417730 | |
ENSP00000262746 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 17655343 | |
ENSP00000262746 | Testicular Cancer | Normal vs. Cancer | cell line | Up | 18489135 | |
ENSP00000262746 | Uterine Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | |
ENSP00000262746 | Uterine Cancer | Treatment(21% oxygen vs. 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | |
ENSP00000262746 | Head and Neck Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | |
ENSP00000262746 | Head and Neck Cancer | Treatment(21% oxygen vs 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | |
ENSP00000262746 | pancreatic ductal adenocarcinoma | Normal vs. Cancer | tissue | Up | 17492507 | |
Hyperphosphorylation site |
PRDX1_HUMAN do not have hyperphosphorylation site. |
Direct Interaction Pair |
Source | Target | Relationship | Resource |
---|---|---|---|
RAF1_HUMAN | PRDX1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
ZAGL2_HUMAN | PRDX1_HUMAN | kinase -> substrate | RegPhos |
CDK4_HUMAN | PRDX1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
CDK1_HUMAN | PRDX1_HUMAN | kinase -> substrate | RegPhos |
Function Annotation |
KEGG Pathway |
KEGG ID | Pathway |
---|---|
hsa04146 | Peroxisome |
Gene Ontology |
GO ID | GO_Term | Evidence | Ontology |
---|---|---|---|
GO:0019430 | removal of superoxide radicals | IEA | biological_process |
GO:0016491 | oxidoreductase activity | IEA | molecular_function |
GO:0016209 | antioxidant activity | IEA | molecular_function |
GO:0042744 | hydrogen peroxide catabolic process | IDA | biological_process |
GO:0005739 | mitochondrion | IEA | cellular_component |
GO:0005782 | peroxisomal matrix | IEA | cellular_component |
GO:0005737 | cytoplasm | IEA | cellular_component |
GO:0005730 | nucleolus | IEA | cellular_component |
GO:0005737 | cytoplasm | IDA | cellular_component |
GO:0001501 | skeletal system development | TAS | biological_process |
GO:0008379 | thioredoxin peroxidase activity | IDA | molecular_function |
GO:0005515 | protein binding | IPI | molecular_function |
GO:0042470 | melanosome | IEA | cellular_component |
GO:0005829 | cytosol | IEA | cellular_component |
GO:0000302 | response to reactive oxygen species | IEA | biological_process |
GO:0042803 | protein homodimerization activity | IEA | molecular_function |
GO:0032872 | regulation of stress-activated MAPK cascade | IEA | biological_process |
GO:0004601 | peroxidase activity | IDA | molecular_function |
GO:0020037 | heme binding | IEA | molecular_function |
GO:0005759 | mitochondrial matrix | IEA | cellular_component |
GO:0005634 | nucleus | IDA | cellular_component |
GO:0042267 | natural killer cell mediated cytotoxicity | IEA | biological_process |
GO:0042802 | identical protein binding | IEA | molecular_function |
GO:0005739 | mitochondrion | IDA | cellular_component |
GO:0051920 | peroxiredoxin activity | IEA | molecular_function |
GO:0034101 | erythrocyte homeostasis | IEA | biological_process |
GO:0008283 | cell proliferation | IEA | biological_process |
GO:0042345 | regulation of NF-kappaB import into nucleus | IEA | biological_process |
GO:0005515 | protein binding | IEA | molecular_function |
GO:0006979 | response to oxidative stress | IEA | biological_process |
GO:0005719 | nuclear euchromatin | IEA | cellular_component |
GO:0055114 | oxidation-reduction process | IEA | biological_process |